Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 35/100

Failure Rate

12.5%

1 terminated/withdrawn out of 8 trials

Success Rate

87.5%

+1.0% vs industry average

Late-Stage Pipeline

25%

2 trials in Phase 3/4

Results Transparency

43%

3 of 7 completed trials have results

Key Signals

3 with results

Enrollment Performance

Analytics

Phase 3

2(50.0%)

N/A

1(25.0%)

Phase 2

1(25.0%)

4Total

Phase 3(2)

N/A(1)

Phase 2(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (8)

Showing 8 of 8 trials

NCT03148665Completed

Saliva-based Detection of CD44

Role: collaborator

NCT03304990Withdrawn

Panomics Relationships in the Epidemiology of Cancer Through In Silico Expression (PRECISE)

Role: lead

NCT03285802Phase 2Completed

Treatment Plan for an Individual Patient With Recurrent Uterine Papillary Serous Carcinoma (UPSC) With PIK3CA Gene Mutation

Role: lead

NCT01566682Completed

A Multi-Center Trial of the ProLung Test™

Role: collaborator

NCT00534365Phase 3Completed

Study Comparing TVT With TVT-SECUR for the Treatment of Stress Urinary Incontinence

Role: collaborator

NCT01377142Completed

Vaginal Uphold Hysteropexy and Laparoscopic Sacral Hysteropexy for the Treatment of Uterovaginal Pelvic Organ Prolapse

Role: collaborator

NCT00629265Not ApplicableCompleted

Efficacy of Electrical Stimulation for Dysphagia in Head & Neck Cancer Patients

Role: collaborator

NCT00475839Phase 3Completed

Study Comparing Tension-free Vaginal Tape With the Monarc Procedure for Stress Urinary Incontinence

Role: collaborator

All 8 trials loaded